PHOTODYNAMIC THERAPY IN TREATMENT OF PATIENTS WITH PREMALIGNANT VULVAR DISEASES. FIRST EXPERIENCE OF THE METHOD APPLICATION IN UKRAINE.

The aim of the study is to evaluate the tolerability and effectiveness of photodynamic therapy (PDT) of patients with premalignant diseases of the vulva. The study was performed on 10 patients on the basis of the National Cancer Institute of Ukraine (Kyiv). The age of patients ranged from 31 to 67 years old (mean age: 53.

[CLINICAL FEATURES OF ENDOMETRIOSIS IN WOMEN IN PERIMENOPAUSE].

The aim of the research is the assessment of the features of the course of endometriosis in women in perimenopause. The exanimated group of patients consisted of 106 women with endometriosis and climacteric syndrome and 64 women with endometriosis without climacteric syndrome. The comparison group consisted of 70 women without endometriosis and symptoms of climacteric syndrome.

[ON THE ISSUE OF AUTOIMMUNE OVARY DAMAGE DURING PUBERTY].

The aim of the study was to ascertain the influence of AІТ on the formation of autoimmune damage to ovaries by determining the connections between the levels of AOAB, ATPO, gonadotropic and sex hormone levels, and the functional state of the ovaries and thyroid gland. 198 girls age 10-18 were studied: 166 with AIT (AIT+ Group), и 32- without AIT (the AIT- Group). A defined difference between TTH.

ENDOMETRIAL POLYPS IN WOMEN OF REPRODUCTIVE AGE: CLINICAL AND PATHOGENE-TIC VARIATIONS.

The aim of the study was to study the relationship between the morphofunctional characteristics of the endometrium, hormonal homeostasis and microbiocenosis of the reproductive system in patients with endometrial polyps. The study involved 130 patients aged 18-35 years: 34 patients with endometrial polyps, 30 patients with micropolyps, 36 patients with endometrial polyps and micropolyps, 30 healthy women of the control group. Hysteroscopy was performed for women who had been suspected for endometrial polyps and who had infertility or repeated recurrent miscarriages.

Ulipristal acetate versus placebo for fibroid treatment before surgery.

Background: The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain.

Methods: We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding]) and anemia (hemoglobin level of ≤10.2 g per deciliter) to receive treatment for up to 13 weeks with oral ulipristal acetate at a dose of 5 mg per day (96 women) or 10 mg per day (98 women) or to receive placebo (48 women).